Elina S. Rantala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Elina S. Rantala has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Tero Kivelä
Ocular Oncology Service, Department of Ophthalmology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
5 shared publications Tero T. Kivelä
Ocular Oncology Service, Department of Ophthalmology, University of Helsinki and Helsinki University Hospital
3 shared publicationsMicaela Hernberg
Comprehensive Cancer Centre, Department of Oncology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
2 shared publications- Micaela Hernberg
Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
2 shared publications Aino Soro-Paavonen
Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland
1 shared publicationAnna Majander
Helsinki University Eye Hospital Helsinki Finland
1 shared publication
Latest Publications
- Open Access
- 1 November 2022
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 246, 258-272
Determinants of Long-Term Survival in Metastatic Choroidal and Ciliary Body Melanoma
- 1 November 2022
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 246, 258-272
Open AccessDeterminants of Long-Term Survival in Metastatic Choroidal and Ciliary Body Melanoma
- Open Access
- 31 March 2022
- Published by S. Karger AG in Ophthalmic Research
- Vol. 66 (1) , 14-26
Outcome Measures of New Technologies in Uveal Melanoma: Review from the European Vision Institute Special Interest Focus Group Meeting
Uveal melanoma (UM) is the most common primary intraocular tumor in adults. New diagnostic procedures and basic science discoveries continue to change our patient management paradigms. A recent meeting of the European Vision Institute (EVI) special interest focus group was held on “Outcome Measures of New Technologies in Uveal Melanoma,” addressing the latest advances in UM, starting with genetic developments, then moving on to imaging and treatment of the primary tumor, as well as to investigating the most recent developments in treating metastases, and eventually taking care of the patient’s well-being. This review highlights the meeting’s presentations in the context of the published literature.
- 31 March 2022
- Published by S. Karger AG in Ophthalmic Research
- Vol. 66 (1) , 14-26
Open AccessOutcome Measures of New Technologies in Uveal Melanoma: Review from the European Vision Institute Special Interest Focus Group Meeting
Uveal melanoma (UM) is the most common primary intraocular tumor in adults. New diagnostic procedures and basic science discoveries continue to change our patient management paradigms. A recent meeting of the European Vision Institute (EVI) special interest focus group was held on “Outcome Measures of New Technologies in Uveal Melanoma,” addressing the latest advances in UM, starting with genetic developments, then moving on to imaging and treatment of the primary tumor, as well as to investigating the most recent developments in treating metastases, and eventually taking care of the patient’s well-being. This review highlights the meeting’s presentations in the context of the published literature.
- Top Cited PapersOpen Access
- 6 January 2022
- Published by Elsevier in Progress in Retinal and Eye Research
- Vol. 90, 101041
Metastatic uveal melanoma: The final frontier
- 6 January 2022
- Published by Elsevier in Progress in Retinal and Eye Research
- Vol. 90, 101041
Top Cited PapersOpen AccessMetastatic uveal melanoma: The final frontier
- Open Access
- 5 March 2021
- Published by Wolters Kluwer Health in Melanoma Research
- Vol. 31 (3) , 224-231
Impact of staging on survival outcomes: a nationwide real-world cohort study of metastatic uveal melanoma
No data exist regarding whether any first-line treatment for metastatic uveal melanoma provides overall survival (OS) benefit, if staged and compared to best supportive care (BSC). We analyzed OS in a nationwide, consecutive cohort diagnosed with metastatic uveal melanoma between January 1999 and December 2016. The Helsinki University Hospital Working Formulation was used to assign patients to stage IVa, IVb and IVc, corresponding to predicted median OS ≥12, P < 0.001, P = 0.010). In stage IVb and IVc, no difference in OS was observed in any comparison. Staging of patients is crucial when comparing survival after metastatic uveal melanoma. Only surgical resection for stage IVa disease provided longer OS in our national cohort. We additionally recommend stage-specific comparison of novel treatments against available BSC data.
- 5 March 2021
- Published by Wolters Kluwer Health in Melanoma Research
- Vol. 31 (3) , 224-231
Open AccessImpact of staging on survival outcomes: a nationwide real-world cohort study of metastatic uveal melanoma
No data exist regarding whether any first-line treatment for metastatic uveal melanoma provides overall survival (OS) benefit, if staged and compared to best supportive care (BSC). We analyzed OS in a nationwide, consecutive cohort diagnosed with metastatic uveal melanoma between January 1999 and December 2016. The Helsinki University Hospital Working Formulation was used to assign patients to stage IVa, IVb and IVc, corresponding to predicted median OS ≥12, P < 0.001, P = 0.010). In stage IVb and IVc, no difference in OS was observed in any comparison. Staging of patients is crucial when comparing survival after metastatic uveal melanoma. Only surgical resection for stage IVa disease provided longer OS in our national cohort. We additionally recommend stage-specific comparison of novel treatments against available BSC data.
- Open Access
- 22 September 2020
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 60 (1) , 135-139
Metastatic uveal melanoma managed with best supportive care
(2020). Metastatic uveal melanoma managed with best supportive care. Acta Oncologica. Ahead of Print.
- 22 September 2020
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 60 (1) , 135-139
Open AccessMetastatic uveal melanoma managed with best supportive care
(2020). Metastatic uveal melanoma managed with best supportive care. Acta Oncologica. Ahead of Print.
- Open Access
- 1 August 2020
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 216, 156-164
Hepatic Ultrasonography Compared With Computed Tomography and Magnetic Resonance Imaging at Diagnosis of Metastatic Uveal Melanoma
- 1 August 2020
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 216, 156-164
Open AccessHepatic Ultrasonography Compared With Computed Tomography and Magnetic Resonance Imaging at Diagnosis of Metastatic Uveal Melanoma
- 18 May 2020
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 33 (5) , 756-762
Germline loss‐of‐function variants in MBD4 are rare in Finnish patients with uveal melanoma
Uveal melanoma (UM) is a rare intraocular cancer with the highest incidence in northern latitudes. Metastases develop in approximately 50% of patients, whereafter the median survival is 13 months. Generally, the mutation burden of these tumors is low. Germline variants predisposing to UM have been previously described in BRCA1‐associated protein 1 (BAP1). Recently, germline and somatic loss‐of‐function (LOF) variants in the methyl‐CpG‐binding domain 4 (MBD4) gene have been found to cause a hypermutated UM, and MBD4 also has been put forward as a gene predisposing to UM. We sequenced for MBD4 germline variants in 440 Finnish patients with UM and identified seven rare exonic missense variants in 16 (3.6%) patients, of which one likely alters MBD4 function. The frequency of likely pathogenic variants in our cohort is 0.23% (1/432; 95% CI, 0.01–1.28). We identified no LOF variants though their frequency in the Finnish population is 0.052%. Thus, our data do not support the suggestion that MBD4 germline variants predispose to UM. Somatic loss of MBD4 might modify the mutational burden in UM and change its response to immune checkpoint inhibitors.
- 18 May 2020
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 33 (5) , 756-762
Germline loss‐of‐function variants in MBD4 are rare in Finnish patients with uveal melanoma
Uveal melanoma (UM) is a rare intraocular cancer with the highest incidence in northern latitudes. Metastases develop in approximately 50% of patients, whereafter the median survival is 13 months. Generally, the mutation burden of these tumors is low. Germline variants predisposing to UM have been previously described in BRCA1‐associated protein 1 (BAP1). Recently, germline and somatic loss‐of‐function (LOF) variants in the methyl‐CpG‐binding domain 4 (MBD4) gene have been found to cause a hypermutated UM, and MBD4 also has been put forward as a gene predisposing to UM. We sequenced for MBD4 germline variants in 440 Finnish patients with UM and identified seven rare exonic missense variants in 16 (3.6%) patients, of which one likely alters MBD4 function. The frequency of likely pathogenic variants in our cohort is 0.23% (1/432; 95% CI, 0.01–1.28). We identified no LOF variants though their frequency in the Finnish population is 0.052%. Thus, our data do not support the suggestion that MBD4 germline variants predispose to UM. Somatic loss of MBD4 might modify the mutational burden in UM and change its response to immune checkpoint inhibitors.
- Top Cited PapersOpen Access
- 1 December 2019
- Published by Wolters Kluwer Health in Melanoma Research
- Vol. 29 (6) , 561-568
Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis
The overall survival (OS) of patients with metastatic uveal melanoma is short, the evidence for effectiveness of treatments is limited, and no consensus on the choice of treatment exists. We aimed to advance interpretation of OS as an outcome by pooling peer-reviewed data. The design is a systematic review and meta-analysis. We searched PubMed from 1 January 1980, to 29 March 2017, for articles reporting patient-level survival in Kaplan–Meier or numerical form. We digitized survival graphs, pooled individual survival times, calculated median OS by treatment modality, and compared each modality by the log-rank test and Cox regression using conventional chemotherapy (CHT) as a reference. Individual-level data were obtained from 78 articles with 2494 patients. The median OS across all treatment modalities was 1.07 years (range: 0.59–2.50 years). Pooled OS reported after isolated hepatic perfusion [median OS: 1.34 years; hazard ratio (HR): 0.92, 95% confidence interval (CI): 0.87–0.97, P = 0.0040], immunoembolization (median OS: 1.63; HR: 0.97, 95% CI: 0.95–1.00, P = 0.0080), and surgery (median OS: 1.43; HR: 0.94, 95% CI: 0.92–0.96, P < 0.0001) was longer, and after checkpoint inhibitor shorter (median OS: 0.59; HR: 1.13, 95% CI: 1.06–1.20, P < 0.0001) than after CHT (median OS: 0.91 years), but subject to identifiable confounding factors. OS following other modalities did not differ from CHT. Reported OS was unassociated with the decade of publication, but depended on the percentage of first-line treated patients. Our results suggest no clinically significant difference in OS by treatment modality or decade. Most of the difference in reported OS likely is attributable to surveillance, selection, and publication bias rather than treatment-related prolongation. Our pooled data provide benchmarks for future trials.
- 1 December 2019
- Published by Wolters Kluwer Health in Melanoma Research
- Vol. 29 (6) , 561-568
Top Cited PapersOpen AccessOverall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis
The overall survival (OS) of patients with metastatic uveal melanoma is short, the evidence for effectiveness of treatments is limited, and no consensus on the choice of treatment exists. We aimed to advance interpretation of OS as an outcome by pooling peer-reviewed data. The design is a systematic review and meta-analysis. We searched PubMed from 1 January 1980, to 29 March 2017, for articles reporting patient-level survival in Kaplan–Meier or numerical form. We digitized survival graphs, pooled individual survival times, calculated median OS by treatment modality, and compared each modality by the log-rank test and Cox regression using conventional chemotherapy (CHT) as a reference. Individual-level data were obtained from 78 articles with 2494 patients. The median OS across all treatment modalities was 1.07 years (range: 0.59–2.50 years). Pooled OS reported after isolated hepatic perfusion [median OS: 1.34 years; hazard ratio (HR): 0.92, 95% confidence interval (CI): 0.87–0.97, P = 0.0040], immunoembolization (median OS: 1.63; HR: 0.97, 95% CI: 0.95–1.00, P = 0.0080), and surgery (median OS: 1.43; HR: 0.94, 95% CI: 0.92–0.96, P < 0.0001) was longer, and after checkpoint inhibitor shorter (median OS: 0.59; HR: 1.13, 95% CI: 1.06–1.20, P < 0.0001) than after CHT (median OS: 0.91 years), but subject to identifiable confounding factors. OS following other modalities did not differ from CHT. Reported OS was unassociated with the decade of publication, but depended on the percentage of first-line treated patients. Our results suggest no clinically significant difference in OS by treatment modality or decade. Most of the difference in reported OS likely is attributable to surveillance, selection, and publication bias rather than treatment-related prolongation. Our pooled data provide benchmarks for future trials.
- 11 August 2014
- Published by Wiley in Acta Ophthalmologica
- Vol. 93 (3) , e232-e233
Anterior segment optical coherence tomography in autosomal recessive cornea plana
- 11 August 2014
- Published by Wiley in Acta Ophthalmologica
- Vol. 93 (3) , e232-e233
Anterior segment optical coherence tomography in autosomal recessive cornea plana
- Open Access
- 4 November 2010
- Published by Wiley in Acta Ophthalmologica
- Vol. 90 (5) , 441-444
Micropulse diode laser trabeculoplasty – 180‐degree treatment
: Purpose: To evaluate the outcome of 180° micropulse diode laser trabeculoplasty (MDLT) in patients with open‐angle glaucoma.Methods: A retrospective review of 40 eyes of 29 MDLT‐treated patients with a minimum follow‐up time of 6 months. Successful outcome was defined as follows: (i) a ≥20% or (ii) a ≥3‐mmHg decrease of intraocular pressure (IOP), no further need for laser‐ or incisional surgery and the number of glaucoma medication was the same or less than preoperative. These definitions will from now on be referred to as definition one and definition two.Results: Life‐table analysis showed an overall success rate of 2.5% (1/40) and 7.5% (3/40) (according to definitions one and two, respectively) after up to 19 months of follow‐up. The average time for failure was by definition one 2.9 months (standard deviation, SD ± 3.5, range 1–12 months) and by definition two 3.3 months (SD ± 3.9, range 1–16 months). There were no intra‐ or postoperative complications caused by MDLT. Postoperative inflammatory reaction, cells and flare, was scanty.Conclusion: Our results suggest that 180° MDLT is a safe but ineffective treatment in patients with open‐angle glaucoma.
- 4 November 2010
- Published by Wiley in Acta Ophthalmologica
- Vol. 90 (5) , 441-444
Open AccessMicropulse diode laser trabeculoplasty – 180‐degree treatment
: Purpose: To evaluate the outcome of 180° micropulse diode laser trabeculoplasty (MDLT) in patients with open‐angle glaucoma.Methods: A retrospective review of 40 eyes of 29 MDLT‐treated patients with a minimum follow‐up time of 6 months. Successful outcome was defined as follows: (i) a ≥20% or (ii) a ≥3‐mmHg decrease of intraocular pressure (IOP), no further need for laser‐ or incisional surgery and the number of glaucoma medication was the same or less than preoperative. These definitions will from now on be referred to as definition one and definition two.Results: Life‐table analysis showed an overall success rate of 2.5% (1/40) and 7.5% (3/40) (according to definitions one and two, respectively) after up to 19 months of follow‐up. The average time for failure was by definition one 2.9 months (standard deviation, SD ± 3.5, range 1–12 months) and by definition two 3.3 months (SD ± 3.9, range 1–16 months). There were no intra‐ or postoperative complications caused by MDLT. Postoperative inflammatory reaction, cells and flare, was scanty.Conclusion: Our results suggest that 180° MDLT is a safe but ineffective treatment in patients with open‐angle glaucoma.